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Abstract
Background: Stereotactic ablative radiotherapy (SABR) is a treatment option for patients with early stage non-small
cell lung cancer (NSCLC) and recurrent or oligometastatic disease who are not surgical candidates. Due to the
continuous motion of tumors within the lungs, implementing a strategy to track the target lesion is crucial. One
method is to place fiducial markers which the robotic SABR system is able to track during treatment. However,
placing these markers in a manner that maximizes tracking efficacy can be challenging. Using a novel fiducial
placement guidance system (FPGS) during fiducial deployment may offer a way to improve the quantity of fiducials
tracked by the robotic SABR system.
Method: This was an institutional, retrospective review identifying all patients who received robotic SABR for lung
tumors from May 2015 until January 2017. The FPGS was instituted in May 2016. The median number of fiducials
tracked and the rate of complication was compared between patients whose fiducials were placed using FPGS
versus those that were not.
Results: A total of 128 patients with 147 treated lung lesions were identified. Of the lesions that utilized FPGS
(n = 44), 28 had 2 tracked fiducials (63.6%), 14 had 3 (31.8%) and 2 had 4 (4.6%). Of the lesions treated without
FPGS (n = 103), 5 had 1 tracked fiducial (4.9%), 91 had 2 (88.4%), 6 had 3 (5.8%), and 2 had 4 (1.9%). A significant
improvement in the median number of fiducials tracked per fraction was observed for the lesions with fiducials
placed using FPGS on Wilcoxon rank sum test (p < 0.001). The rate of complication was low and not statistically
different between cohorts (p = 0.44).
Conclusions: The FPGS can be used during the deployment of fiducial markers and may increase the number of
fiducials tracked.
Trial registration: An exemption for this retrospective review was granted by the East Carolina University IRB
under UMCIRB 15-001726.
Keywords: Fiducial, Electromagnetic navigational bronchoscopy, SABR, Stereotactic ablative radiotherapy, Lung
cancer, CyberKnife, SBRT
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Background
The preferred treatment for patients with early stage
NSCLC is surgical resection. However, comorbidities
such as chronic obstructive pulmonary disease and car-
diovascular disease exclude an estimated 25% of these
patients from being candidates for lobectomy [1]. In the
past, those patients who were deemed inoperable were
typically offered conventional radiotherapy or observa-
tion. Those who chose conventional radiotherapy had a
60–70% chance of failure to control the primary tumor
[2–4]. Patients who chose observation had a more than
50% chance of dying from cancer progression [5, 6]. Un-
fortunately, the 2-year survival for either approach is less
than 40%. With the development of SABR, it became
possible to deliver highly conformal, high-dose radiation
to target lesions. SABR was found to be a major im-
provement on conventionally fractionated radiotherapy
for non-operable, early stage NSCLC patients, and offers
a much higher primary tumor control rate of as high as
97.6% at 3 years [6]. Due to the elliptical motion of the
lungs during the respiratory cycle, tumor motion has
been a major technical obstacle [7].
There are differing strategies that are used to account
for tumor motion during SABR in lung tumors: to
immobilize the target (via breath holding techniques or
abdominal compression), to gate the beam so that it is
only delivering in a certain portion of the patient’s
breathing cycle, or to actively track the target during
breathing motion [8]. The robotic SABR system utilizes
active tracking by adjusting for changes in target pos-
ition throughout the respiratory cycle [9]. This delivery
technique tracks the target either via tumor visualization
using orthogonal radiographs that match intensity pat-
tern variation of the target during treatment or by rely-
ing on fiducial markers [10]. Compared to the other
strategies of accounting for target motion, our center felt
more confident with a tighter expansion from tumor to
planning target volume with the active tracking of a ro-
botic system. However, in order for robotic SABR to be
safe and effective, good fidelity in tracking has to be en-
sured. At our institution, pulmonologists utilize electro-
magnetic navigational bronchoscopy (ENB) to place
fiducial markers. In order to best track the tumor in a
variety of conditions, fiducials must be positioned in, or
in close proximity to, the target area so that their move-
ment coincides with the target’s motion [11]. As long as
there are at least three fiducials tracked, the robotic
SABR can potentially track lesions in 6D and adjust the
treatment frame of reference. Our institutional prefer-
ence is to place one fiducial within the tumor, or at the
biopsy site when placement is combined with a biopsy,
and the others around the tumor. Ideally, fiducials
should be > 2 cm apart from each other and form an
angle of > 15 degrees for 6D tracking [12, 13].
Once the fiducial markers are in place, an imaging sys-
tem that utilizes the two orthogonal x-ray sources in
conjunction with amorphous silicon detectors acquires
live imaging of the patient during treatment, allowing
for real-time imaging of the fiducials. Superficially placed
infrared light-emitting diodes (LEDs) on the abdomen
are monitored on a separate camera array. The tracking
system then creates a predictive model where the mo-
tion of the fiducials on the orthogonal x-rays through
the phases of the breathing cycle is correlated with the
breathing phase data derived from the infrared LEDs.
This enables the robotic SABR to continuously predict
the motion of the fiducials and tumor via the movement
of the LEDs and to ensure that the treatment beam is on
target despite system latency [13]. This system requires a
minimum of 1 fiducial to track the translational motion
of the tumor, and at least 3 fiducials for 6D tracking of
the translations and rotations of the target [12].
Inserting fiducials with minimal complications may be
difficult. The bronchoscopic technique has been proven
to have a more desirable side effect profile when com-
pared to the other two options [14–16]. For example,
when using the CT-guided percutaneous placement
method via an 18-gauge needle, Bhagat et al. found a
pneumothorax rate of 67% [17]. When using a 19-gauge
needle for the same approach, Kothary et al. had a 45%
pneumothorax development rate [18]. The ENB modal-
ity is an all-inclusive and minimally morbid management
strategy for inoperable, early-stage NSCLC patient popu-
lation [19]. In a study performed by Harley et al. analyz-
ing the efficacy of endobronchial ultrasound and ENB-
based fiducial placement, only one of the 48 patients in-
cluded in the study developed a pneumothorax [20].
Furthermore, unlike other techniques, ENB affords the
opportunity to stage the mediastinum via endobronchial
ultrasound, to biopsy the primary tumor, and to place fi-
ducials all during a single procedure. Though achieving
all three goals during one procedure lengthens the time
to completion, it is thought that this three-in-one
method could expedite management of lung cancer and
reduce the overall rate of complications [21].
ENB has improved upon the standard bronchoscopic
method for the placement of fiducials in thoracic tu-
mors. ENB is an image-guided approach that uses a 3D-
reconstructed CT-scan and an electromagnetic field
board to access peripheral lung lesions beyond the reach
of conventional bronchoscopes in real time [22]. The
American College of Chest Physicians (ACCP) guidelines
have recommended ENB for the evaluation of peripheral
lung lesions that cannot be reached by conventional
bronchoscopy [23]. This system combines the strengths
of three tools in order to reach its target. Firstly, a CT
scan is obtained in order to recreate a 3-D virtual recon-
struction of the airways. Secondly, an eight-way steerable
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probe that possesses a position sensor is piloted through
the endobronchial tree. Lastly, an electromagnetic board
is connected to a computer containing the planning
data. This board is able to track the location of the probe
tip and relay the information to the treatment console
being viewed by the pulmonologist, thus giving the oper-
ator real-time positional information within the bron-
chial tree [24].
A novel fiducial placement guidance system (FPGS) was
developed for use during an ENB procedure. The FPGS
suggests target locations for fiducial placement that are in
an optimal geometry for detection on orthogonal x-rays ac-
quired by the robotic SABR delivery system (Fig. 1). These
locations are generated after surveying the region around
the tumor for fiducial placement targets that are accessible
by bronchoscope. The FPGS creates a “map” for the pul-
monologists to navigate to these suggested locations and to
place fiducials at their ideal parameters of > 2 cm apart
from each other and form an angle of > 15 degrees for 6D
tracking [11]. The fiducial locations are calculated to be in
smaller airways to minimize fiducial migration.
This study will focus on analyzing the results obtained
with and without the use of FPGS to determine whether
the implementation of the placement system had a posi-
tive impact on fiducial tracking in the robotic SABR sys-
tem in our institution. The primary study aim was to
assess the efficacy of the FPGS’ ability to increase the
number of fiducials tracked during robotic SABR therapy.
Methods
Patients
This is an institutional retrospective review that includes
all patients who received robotic SABR for lung tumors
from May 2015 until January 2017. The type of lesions
included in this study consist of presumptive stage I
NSCLC, pathologically confirmed stage IA, IB, and IIA
NSCLC, metastatic lesions to the lung from extrathor-
acic primary tumors, locally recurrent NSCLC, and pa-
tients previously treated with SABR who subsequently
developed either a second lung primary or developed
metastatic disease. Those who were considered pre-
sumptive stage I had insufficient material for definitive
diagnosis or had a PET-positive lesion that could not be
biopsied. Metastatic lesions were included in the FPGS
cohort since the use of SABR to treat oligometastatic
lung lesions became a more widely accepted practice
Fig. 1 Fiducial placement guidance system example. A screenshot from the FPGS system during the fiducial placement procedure. The green
sphere represents the tumor and suggested targets for placement of a fiducial as specified by the FPGS are marked in yellow
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during this time frame. We excluded patients with tu-
mors primary located in the chest wall, patients treated
with more than 10 fractions, and patients who were
treated with spine tracking or fiducial-based tracking
without respiratory motion management.
This study compares lesions treated by SABR where fi-
ducials were placed using ENB with the FPGS versus le-
sions that did not utilize the guidance system for fiducial
placement. Within the non-FPGS cohort, 2 patients had
their fiducials placed under CT guidance by interventional
radiology, 1 other patient had fiducials placed under con-
ventional bronchoscopy with fluoroscopic guidance, and 1
patient had their fiducials placed at an outside institution
where the method of placement could not be determined.
The FPGS was instituted in May 2016. The superDimen-
sion Navigation System (superDimension, Inc., Plymouth,
MN) was used in ENB, the FPGS was developed by Med-
tronic (Dublin, Ireland) as an add-on to the superDimen-
sion navigational system, with developmental input from
one of the authors of this study, M.B. The number of fidu-
cials tracked per fraction by the Cyberknife (Accuray, Inc.,
Sunnyvale, CA) Synchrony respiratory motion manage-
ment system during robotic SABR was compared between
lesions with fiducials placed using FPGS versus those that
did not; complication rates were also compared.
A total of 128 patients with 147 treated lung lesions
were identified. Of the total 147 lung lesions, 39 were pre-
sumptive Stage I NSCLC, 29 were Stage IA, 11 were Stage
IB, 3 were Stage IIA NSCLC, 41 were metastatic tumors
of various primary sites, 8 were locally recurrent NSCLC,
11 were either a second primary or Stage IV NSCLC, and
5 other lesions did not fit the above categories (Table 1).
The anatomical locations of the lesions included 39 right
upper lobe (26.5%), 6 right middle lobe (4.1%), 27 right
lower lobe (18.4%), 42 left upper lobe (28.6%), and 33 left
lower lobe (22.4%) (Fig. 2). Of the total 147 lesions, 44
(29.9%) had fiducials placed by FPGS and 103 (70.1%) did
not. The median fractions for both cohorts combined was
5 (range 3–10) with a median dose of 60Gy (range 24–60
Gy). Fiducial placement related complications were de-
fined based on the Common Terminology Criteria for Ad-
verse Events (CTCAE) scale version 4 [24, 25].
Statistics
The primary study aim was to assess the ability of the FPGS
to increase the number of fiducials tracked during robotic
SABR therapy. Patients were divided into cohorts based on
whether or not the FPGS was used. For each treated lesion,
the median of the number of fiducials tracked per fraction
was calculated. One patient in the non-FPGS cohort had a
median of 1.5 fiducials tracked in his course of treatment,
for analysis this was rounded up to 2. Clinical factors that
were evaluated included cancer Stage, anatomic location of
tumors, complications, number of fiducials tracked, and
total number of fractions received. Descriptive analysis was
used to calculate the percentages, means and medians be-
tween cohorts. The Wilcoxon rank sum test was used to
test for significance, with p < 0.05 being considered statisti-
cally significant. Statistical calculations were conducted
using the MedCalc12.6.00 (Medcalc, Mariakerke, Belgium)
statistical package.
Results
Complications for fiducials placed in lesions that used
the FPGS (n = 44) included pneumothorax (2.27%) and
bleeding (2.27%), CTCAE Grade I and II, respectively.
For the lesions that did not utilize the FPGS (n = 103),
complications included one incidence of Grade II
pneumothorax (0.97%). The non-FPGS cohort did also
have two incidences of hypoxia and one of hypotension.
However, these events were not used in the assessment
of intervention-related complications as per Trotti et al.
in the development of CTCAE [24]. The rate of compli-
cation was not statistically different between cohorts
(p = 0.44). None of the 4 patients in the non-FPGS co-
hort who were not recorded to have utilized ENB had a
documented toxicity.
Table 1 Lesion characteristics. This table categorizes the lesions based on stage and whether or not the FPGS was used










Presumptive Stage I 22 21.36% 17 38.64% 39
Actual Stage IA 22 21.36% 7 15.91% 29
Actual Stage IB 8 7.77% 3 6.82% 11
Actual Stage IIA 3 2.91% 0 0.00% 3
Metastatic 30 29.13% 11 25.00% 41
Locally Recurrent 7 6.80% 1 2.27% 8
Second Primary vs.
Stage IV
8 7.77% 3 6.82% 11
Other 3 2.91% 2 4.55% 5
Total 103 44 147
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The median number of fiducials implanted using the
endobronchial navigation was 4 in both cohorts (range
2–5 for FPGS, range 3–6 without FPGS, though not re-
corded in 12 of the patients in the FPGS cohort). Only 1
patient in the study, who was in the FPGS cohort, had
less than 3 fiducials implanted. Of the lesions that uti-
lized FPGS (n = 44), 28 had a median of 2 fiducials
tracked by the SABR system (63.6%), 14 had 3 (31.8%)
and 2 had 4 (4.6%). Of the lesions treated without FPGS
(n = 103), 5 had 1 tracked fiducial (4.9%), 91 had 2
(88.4%), 6 had 3 (5.8%), and 2 had 4 (1.9%) (Fig. 3). An
example of a patient with 4 fiducials tracked on the ro-
botic SABR system after using the FPGS for placement
can be seen in Fig. 4. A significant improvement in the
Fig. 2 Anatomical location of lung lesions. Number of lesions, and the percent of the total number of lesions, located in each lobe of the lung
Fig. 3 Fiducials tracked . Comparison of the distribution of the percentage of fiducials tracked in cases that did not use the FPGS (solid column)
vs. cases that did utilize the FPGS (striped column)
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median of fiducials tracked per fraction was observed in
the lesions with fiducials placed using FPGS (p < 0.001),
including an increase in the percentage of patients where
3 fiducials were tracked, which was the minimum re-
quired for potential rotational correction as well as
translational correction in the robotic SABR system.
Discussion
In our retrospective study, a total of 4.55% (n = 2) of the
lesions with fiducials placed using ENB with FPGS de-
veloped complications, and in the non-FPGS cohort,
0.97% (n = 1) developed CTCAE defined complications.
When analyzing all of the lesions where the fiducials
were confirmed to have been placed by ENB (n = 143), a
total of 2.04% (n = 3) patients in this study developed
complications. We will note that the two that developed
a pneumothorax were undergoing concurrent biopsy
and fiducial placement. The overall rate of complications
seen in this study is comparable to other studies which
demonstrate that patients who receive ENB-placed fidu-
cials are less likely to develop adverse effects when com-
pared to the percutaneous method [16, 19].
Our study showed a significant improvement on the
number of patients with at least three fiducials tracked
when using the FPGS (36.36% vs 7.77%), thus increasing
the possibility of 6D tracking. However, despite the im-
provements in the number of fiducials tracked, not all
patients had three fiducials tracked, so there are still im-
provements to be made on the system. For example, the
FPGS at its current version does not take into account
the possibility that fiducials could shadow each other on
the orthogonal x-rays used in the robotic SABR system
when suggesting placement positions for fiducials. In
addition, tracking three fiducials does not always result
in 6D tracking. This is perhaps due to the more expan-
sile nature of the lung tissue causing issues in assessing
rotations, as compared to other organs that are treated
with robotic SABR, such as the prostate.
This study is limited by its retrospective design. The
retrospective nature lends to selection bias and incom-
plete patient, tumor, and treatment details that may
otherwise be captured in a prospective study. There was
also a specific date in which our institution began imple-
menting the FPGS for most patients, which could intro-
duce additional bias as the pulmonologists performing
the procedure could gain more experience over time.
However, the principle pulmonologist who placed the fi-
ducials both before and after the initiation of the FPGS
had several years of experience using ENB prior to the
time period included in this cohort, and there was a
steep increase in the median of fiducials tracked imme-
diately after FPGS implementation (Fig. 5). This suggests
it was not merely an accumulation of improved experi-
ence using the new system that improved tracking. The
data for the number of fiducials that were implanted is
missing for 12 patients in the non-FPGS system cohort,
however 2 of those non-FPGS patients with missing data
had 3 fiducials tracked on SABR, and the rest had 2 fi-
ducials tracked, resulting in a mean and median for
tracked fiducials in those 12 patients of 2.17 and 2 re-
spectively. This appears to be reflective of the distribu-
tion of the remainder of the non-FPGS cohort, and we
Fig. 4 Fiducial tracking during treatment. An example of the robotic SABR system tracking 4 fiducials on orthogonal cameras during treatment
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do not feel as though this would significantly affect the
overall analysis of this study. Another potential con-
founding factor of this study is that the indications for
lung SABR had been expanding over the period in which
the FPGS system was implemented, particularly a rela-
tive increase over time of the patients being treated for
oligometastatic disease, however the overall percentage
of the different indications for SABR remained relatively
comparable between the FPGS and non-FPGS cohorts,
as shown in Fig. 1. Despite these limitations, this study
provides important information with regards to the
safety and efficacy of a FPGS when placing fiducials for
patients with NSCLC.
Conclusions
Our retrospective study showed that using the FPGS
resulted in a statistically significant improvement in the
median of fiducials tracked during robotic SABR ther-
apy. Fiducial placement using the FPGS did not result
in an increase in placement-related complications. Add-
itional research is needed to continue to improve the
number of tracked fiducials.
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